In vitro studies with two human organic anion transporters: OAT2 and OAT7

Sumathy MathialaganPharmacokinetics, Dynamics, & Metabolism, Medicine Design, Pfizer Inc, Groton, CT, USA,

Chester CostalesPharmacokinetics, Dynamics, & Metabolism, Medicine Design, Pfizer Inc, Groton, CT, USA,

Laurie TylaskaPharmacokinetics, Dynamics, & Metabolism, Medicine Design, Pfizer Inc, Groton, CT, USA,

Emi KimotoPharmacokinetics, Dynamics, & Metabolism, Medicine Design, Pfizer Inc, Groton, CT, USA,

Anna VildhedePharmacokinetics, Dynamics, & Metabolism, Medicine Design, Pfizer Inc, Groton, CT, USA,

Jillian JohnsonPharmacokinetics, Dynamics, & Metabolism, Medicine Design, Pfizer Inc, Groton, CT, USA,

Nathaniel JohnsonPharmacokinetics, Dynamics, & Metabolism, Medicine Design, Pfizer Inc, Groton, CT, USA,

Takami SarashinaSekisui Medical Co., Ltd, Tokyo, Japan, and

Kenta HashizumeSekisui Medical Co., Ltd, Tokyo, Japan, and

Caleb D. IsringhausenSekisui XenoTech, LLC, Kansas City, KS, USA

Lydia M. M. VermeerSekisui XenoTech, LLC, Kansas City, KS, USA

Andrea R. WolffSekisui XenoTech, LLC, Kansas City, KS, USA

A. David RodriguesPharmacokinetics, Dynamics, & Metabolism, Medicine Design, Pfizer Inc, Groton, CT, USA, Correspondence[email protected]

Your download is now in progress and you may close this window